Hemostatic resuscitation with plasma and platelets in trauma

Autor: Pär I Johansson, Roberto S Oliveri, Sisse R Ostrowski

Publikováno v: Journal of Emergencies, Trauma and Shock, Vol 5, Iss 2, Pp 120-125 (2012)

Background: Continued hemorrhage remains a major contributor of mortality in massively transfused patients and controversy regarding the optimal management exists although recently, the concept of hemostatic resuscitation, i.e., providing large amoun

Externí odkaz: https://doaj.org/article/1ebfa9aeb7614fa99bafedb4a22810b4

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

Autor: Antonio Uccelli, Alice Laroni, Rehiana Ali, Mario Alberto Battaglia, Morten Blinkenberg, Lou Brundin, Michel Clanet, Oscar Fernandez, James Marriott, Paolo Muraro, Seyed Massood Nabavi, Roberto S Oliveri, Ernst Radue, Cristina Ramo Tello, Irene Schiavetti, Johann Sellner, Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mark S Freedman, Naser Aghdami, Eduardo Agüera-Morales, David Allan, Leila Arab, Mario Battaglia, Isabelle Berry, Bruno Bonetti, Chiara Capelli, Lucio Castellan, Maria Cellerino, Maria Teresa Cencioni, Giancarlo Comi, David Courtman, Francesco Dazzi, Anne Fischer-Nielsen, Victoria Fernandez, Mark S. Freedman, Roberto Furlan, Mario Gimona, Francesca Gualandi, Qingdong Guan, Ellen Iacobaeus, Matilde Inglese, Martino Introna, Guillermo Izquierdo, Shahedeh Karimi, Katarina Le Blanc, Sandra Loaiza, Shahrukh Mallik, Stephen Marley, Ruth Ann Marrie, James Marriot, Gianvito Martino, David Miller, Paolo A. Muraro, Richard Nicholas, Giovanni Orengo, Renuka Palanicawande, Matteo Pardini, Ernst W Radue, Carolina Rush, Luc Sensebe, Dirk Strunk, David Szwajcer, Claire Thalamas

Publikováno v: LANCET NEUROLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Summary Background Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a835d6b9db04107af54813a97700f6f0
https://doi.org/10.1016/s1474-4422(21)00301-x

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Autor: Rogier Mous, Ada Azaryan, Brian Elliott, Tommy Li, Dena DeMarco, Martine E.D. Chamuleau, Kim Linton, David John Lewis, Anna Sureda Balari, Roberto S. Oliveri, Pieternella J. Lugtenburg, Martin Hutchings, Michael Roost Clausen, Kuo mei Chen, Tahamtan Ahmadi, David Cunningham, Peter Johnson, Christopher Chiu

Publikováno v: The Lancet, 398(10306), 1157-1169. Elsevier Limited
The Lancet, 398(10306), 1157-1169. Elsevier Ltd.
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8

BACKGROUND: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af475f2eb2549d35a7595f199ce1bd0f
https://research.vumc.nl/en/publications/f3dfa4ae-9861-4d28-8f31-26e4b87ec3e5

O17-1 Subcutaneous (SC) epcoritamab induces complete responses across R/R B-cell NHL subtypes: Updated dose-escalation data

Autor: David John Lewis, Rogier Mous, David Cunningham, Peter Johnson, Kuo-mei Chen, Martin Hutchings, Dena DeMarco, Anna Sureda Balari, Brian Elliott, Martine E.D. Chamuleau, Michael Roost Clausen, Kim Linton, Roberto S. Oliveri, Pieternella J. Lugtenburg

Publikováno v: Annals of Oncology. 32:S292

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33fa2c8bb42af361d1148835a2d4367f
https://doi.org/10.1016/j.annonc.2021.05.546

Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Autor: Frederikke Lihme Egerod, Tommy Li, Theodora W. Salcedo, Manish Gupta, Christopher Chiu, Roberto S. Oliveri, Ida H. Hiemstra, Dena DeMarco

Publikováno v: Blood. 136:35-36

Introduction: Epcoritamab (DuoBody-CD3×CD20) is a subcutaneously administered bispecific antibody (bsAb) that simultaneously binds to CD3 on T cells and CD20 on malignant B cells, resulting in T-cell activation and expansion and selective T-cell-med

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f17673b2dffec8b2e7a5e5bec72939f7
https://doi.org/10.1182/blood-2020-139457